Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. [electronic resource]
- Clinical and experimental rheumatology
- S46-53 p. digital
Publication Type: Journal Article; Review
0392-856X
Adolescent Adult Amyloidosis--blood Anti-Inflammatory Agents--adverse effects Antibodies, Monoclonal, Humanized--adverse effects Biomarkers--blood Child Chronic Disease Databases, Factual Down-Regulation Female Humans Immunocompromised Host Inflammation--blood Interleukin-6--antagonists & inhibitors Male Middle Aged Opportunistic Infections--chemically induced Quality of Life Receptors, Interleukin-6--antagonists & inhibitors Remission Induction Risk Factors Serum Amyloid A Protein--metabolism Signal Transduction--drug effects Surveys and Questionnaires Time Factors Treatment Outcome Young Adult